NEW COGNITIVE TREATMENT FOR EARLY ALZHEIMER'S DISEASE

描述（来自应用程序）：认知康复已被证明可以 有效治疗各种神经系统疾病，包括 创伤性脑损伤和中风。直到最近， 一项研究调查了这种治疗方式的效用， 因为假设任何收益都将被抵消， 与退行性疾病过程相关的进行性恶化。 然而，有数据表明，间隔等技术 检索”和其他依赖于程序知识的技术， 内隐记忆，运动学习和提供认知支持， 信息的编码和检索都可能对轻度有益 AD患者。 最近推出的胆碱酯酶抑制剂，如多奈哌齐（安理申） 已经被经验证明可以减缓AD的认知进展， 他们指出，他们可能会提高认知康复的功效， 在疾病早期进行干预。的 联合认知康复与 药物治疗AD是令人兴奋的，鉴于更新和更多的承诺， 有效的药理学药物在这种情况下的未来。这 对优化和维持患者的认知能力有重要意义 和功能独立的最长时间。 拟议的研究是一个新的系统认知再培训的评价 增强和维持认知和功能状态的方案 接受胆碱酯酶抑制剂（多奈哌齐）的AD患者。除了 其最先进的认知方法，目前的理论驱动的范式 在另外两个方面是独一无二的：它结合了强大的功能， 组分及其作为治疗扩展剂的主要护理者的用途， 促进推广和维护临床取得的成果， 患者的日常生活。虽然先前的努力包括一个 或其中两个元素孤立，没有以前的计划提供了这一点， 一种综合治疗AD的方法， 接受有效的药理学试剂。除了直接 有益于AD患者，建议的认知康复干预是 还有望减少照顾者的感知负担和心理 痛苦

DESCRIPTION (from the application): Cognitive Rehabilitation has been shown to be effective in treating a variety of neurological disorders including traumatic brain injury and stroke. Until recently, there has been a paucity of research investigating the utility of this therapeutic modality with mildly impaired AD patients because of the assumption that any gains would be offset by progressive deterioration associated with the degenerative disease process. There is, however, data that suggest that techniques such as spaced retrieval" and other techniques which rely on procedural knowledge and implicit memory, motor learning and the provision of cognitive support at both encoding and retrieval of information can be beneficial to mildly impaired AD patients. The recently introduced cholinesterase inhibitors such as Donepezil (Aricept) have been empirically shown to slow the cognitive progression of AD to the point that they may enhance the efficacy of cognitive rehabilitation interventions when introduced early in the course of the illness. The potential synergistic effects of combined cognitive rehabilitation with pharmacological agents in AD is exciting, given the promise of newer and more effective pharmacological agents for this condition in the future. This has important implications for optimizing and maintaining the patient's cognitive and functional independence for the longest period of time. The proposed study is an evaluation of a new systematic cognitive retraining program for enhancing and maintaining the cognitive and functional status of AD patients receiving a cholinesterase inhibitor (Donepezil). In addition to its state of the-art cognitive approaches, the present theory-driven paradigm is unique in two other ways: its incorporation of a strong functional component and its use of the primary caregiver as a therapy extender to promote generalization and maintenance of gains attained in the clinical setting to the patient's everyday life. While prior efforts have included one or two of these elements in isolation, no previous program has offered this type of integrated approach in the treatment of AD among individuals who are receiving an effective pharmacological agent. In addition to the direct benefit to AD patients, the proposed cognitive rehabilitation intervention is also expected to reduce the caregiver's perceived burden and psychological distress.